The Future of Tumor Immunology

Cinader, B.

doi:10.1016/s0025-7125(16)32394-x

Cited by 12 publications

(4 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Possibly, the presence of C57B 1/6 antigens on BDFi cells interferes with the recognition of the DBA/2 antigens also present on the FI cells. Alternatively, antigen density on the membranes of the F1 cells may be limiting in this case (7).…”

Section: T U M O R I N D U C T I O N O F a U T O I M~u N E -L I K Ementioning

confidence: 99%

Mixed Lymphocyte Reactivity Against Normal Cells by Splenic Lymphocytes From Tumor-Bearing Mice

Devlin

McCurdy

Baronowsky

1974

The Journal of Experimental Medicine

View full text Add to dashboard Cite

A possible consequence of an antilymphocytic autoimmune process would be serious impairment of an animal's ability to destroy tumor cells. One measure of autoimmune reactivity of this type would be the demonstration of cellular immune responsiveness by cells from tumor-bearing mice against syngeneic normal cells. These experiments demonstrate that spleen cells from mice bearing a lymphocytic leukemia of identical histocompatability type as the host mounted a vigorous immune response against normal syngeneic cells in a mixed lymphocyte reaction (MLR). Moreover, ascitic cells from leukemic mice responded significantly to normal syngeneic spleen cells in MLR's. The former reactions are usually much more vigorous than the responses of normal to malignant cells. These results are discussed in terms of the relationship between autoimmunity and neoplasia. Alternative explanations necessitated by the dangers involved in the interpretation of the immunology of transplantable tumors are considered.

show abstract

Section: T U M O R I N D U C T I O N O F a U T O I M~u N E -L I K Ementioning

confidence: 99%

Mixed Lymphocyte Reactivity Against Normal Cells by Splenic Lymphocytes From Tumor-Bearing Mice

Devlin

McCurdy

Baronowsky

1974

The Journal of Experimental Medicine

View full text Add to dashboard Cite

show abstract

“…Moreover, the liberation of certain pathological tissue proteins in the blood circulation and in the urine might improve diagnosis in certain diseases. For example, we now identity «-fetoprotein (a-FP) and carcino-embryonic antigen (CEA) in human as well as in experimental cancer [15], some kidney antigens in several renal diseases [16] and hepatic antigens in different lesions of the liver [17,18]. Concerning more specifically the kidney, we have used in our laboratories immunochemical methods to identify several mouse and rat tissue antigens [19,20]: data have also been obtained by other workers in the calf [21] and in man [22,23].…”

Section: Introductionmentioning

confidence: 99%

Immunochemical and Enzymatic Studies on the Soluble Antigens of Normal Human Kidney

Dinh¹,

Brassard²,

Raghavan³

et al. 1976

Nephron

View full text Add to dashboard Cite

The antigenic composition of the soluble extract from normal human kidney was determined with the combined techniques of immunological absorption, immunodiffusion and immunoelectrophoresis. The kidney extract contained at least eleven nonserum, tissue antigens; some of them were found in the extracts of other organs, but three were kidney-specific. None of the soluble tissue antigens from human kidney was characterized as a lipoprotein; however, three of them stained with the reagent for glycoproteins. Esterase activities were also demonstrated in four non-serum, renal antigens, one of which was present only in the kidney extract and absent in the other organs extracts.

show abstract

“…The possible relationship of immunologic defenses to survival of patients with malignant disease has been the subject of many reports (8). It is currently believed that antibody-mediated responses to tumors may, in some instances, enhance growth of tumors and, in others, be toxic to malignant cells; cell-mediated immunity usually inhibits growth of tumors (9,10).…”

Section: Introductionmentioning

confidence: 99%

Osteogenic sarcoma. Immunologic parameters before and during immunotherapy with tumor-specific transfer factor.

Levin¹,

Byers²,

Fudenberg³

et al. 1975

J. Clin. Invest.

View full text Add to dashboard Cite

A B S T R A C T 18 patients with osteogenic sarcoma were followed by serial measurements in vitro of tumorspecific cell-mediated cytotoxicity and of "active" and total rosette-forming T-cells. 13 of these patients have had or are currently receiving injections of osteogenic sarcoma-specific dialyzable transfer factor derived from healthy donors. In three patients with very small lesions, cytotoxicity was high before amputation and decreased within 2 mo after removal of tumor. Cytotoxicity was low at time of diagnosis in all patients with large tumor masses. The cytotoxicity of the patients' lymphocytes increased after administration of tumor-specific transfer factor in all patients so treated. Patients receiving nonspecific transfer factor showed evidence of declining cell-mediated cytotoxicity.Tumor-specific transfer factor may produce an increase in cell-mediated cytotoxicity to the tumor in patients with osteogenic sarcoma. This possibility is suggested by the pain and edema that occurred in the area of the tumor in patients who had metastatic disease when therapy was started and by lymphocytic infiltrates in the tumor, as well as by the increase in cell-mediated cytotoxicity and the increase in percentage of active rosette-forming cells from subnormal to normal. Serial measurements of cell-mediated cytotoxicity are helpful in monitoring the efficacy of transfer factor and other modes of therapy in these patients, and these measurements are the best available criteria for selection of donors of tumor-specific transfer factor.

show abstract

The Future of Tumor Immunology

Cited by 12 publications

References 132 publications

Mixed Lymphocyte Reactivity Against Normal Cells by Splenic Lymphocytes From Tumor-Bearing Mice

Mixed Lymphocyte Reactivity Against Normal Cells by Splenic Lymphocytes From Tumor-Bearing Mice

Immunochemical and Enzymatic Studies on the Soluble Antigens of Normal Human Kidney

Osteogenic sarcoma. Immunologic parameters before and during immunotherapy with tumor-specific transfer factor.

Contact Info

Product

Resources

About